Little Green Pharma Ltd. (AU:LGP)
ASX:LGP
Want to see AU:LGP full AI Analyst Report?
Top Page
Little Green Pharma Ltd.
(Sydney:LGP)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.08
â–Ľ(-25.00% Downside)
Action:Reiterated
Date:06/12/26
Overall score reflects weak operating cash generation and inconsistent profitability despite a conservatively levered balance sheet. Technical indicators are bearish (below major moving averages with negative MACD), while valuation is supportive due to a very low P/E.
Positive Factors
Conservative balance sheet
A low leverage profile relative to a sizable equity base gives the company financial flexibility to fund regulatory compliance, capital needs or absorb revenue volatility without immediate refinancing. This balance sheet strength supports multi‑quarter resilience and optionality for strategic investment.
Negative Factors
Weak cash generation
Persistently negative free cash flow, despite improvement, means the business still does not reliably fund growth from operations. This increases reliance on external capital for capex, inventory and working capital, heightens dilution risk, and limits long‑term reinvestment flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low leverage profile relative to a sizable equity base gives the company financial flexibility to fund regulatory compliance, capital needs or absorb revenue volatility without immediate refinancing. This balance sheet strength supports multi‑quarter resilience and optionality for strategic investment.
Read all positive factors
Little Green Pharma Ltd. (LGP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$66.42M
Dividend YieldN/A
Average Volume (3M)234.87K
Price to Earnings (P/E)2.8
Beta (1Y)0.84
Revenue Growth15.21%
EPS Growth-141.82%
CountryAU
Employees94
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding819,978,700
10 Day Avg. Volume223,605
30 Day Avg. Volume234,865
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Little Green Pharma Ltd. Business Overview & Revenue Model
Company Description
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medi...
How the Company Makes Money
LGP makes money primarily by selling medicinal cannabis products into regulated medical markets. Its core revenue model is product-based: it cultivates cannabis (including greenhouse/indoor production where applicable), processes it into medical-g...
Little Green Pharma Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
74
Positive
Cash Flow
35
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.42M | 36.82M | 19.57M | 14.04M | 7.00M |
| Gross Profit | 11.73M | 25.26M | 11.98M | 4.51M | 5.78M |
| EBITDA | 1.85M | -684.00K | -4.64M | -27.03M | 25.38M |
| Net Income | -1.41M | 3.32M | -9.21M | -24.07M | -4.36M |
Balance Sheet | |||||
| Total Assets | 93.75M | 96.12M | 98.62M | 95.95M | 110.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 2.38M | 12.40M | 20.09M | 40.27M |
| Total Debt | 4.69M | 4.67M | 11.87M | 15.87M | 1.42M |
| Total Liabilities | 10.72M | 11.11M | 16.39M | 20.47M | 17.10M |
| Stockholders Equity | 83.03M | 85.02M | 82.23M | 75.48M | 93.89M |
Cash Flow | |||||
| Free Cash Flow | -790.00K | -1.15M | -11.87M | -24.83M | -6.21M |
| Operating Cash Flow | 39.00K | -917.00K | -6.94M | -17.17M | -5.15M |
| Investing Cash Flow | -948.00K | -1.14M | -14.03M | -7.66M | -12.73M |
| Financing Cash Flow | 25.00K | -530.00K | 13.03M | 4.73M | 53.87M |
Little Green Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$20.21M | 25.77 | 1.66% | 3.28% | 2.11% | -64.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$66.42M | 2.83 | 10.34% | ― | 15.21% | -141.82% | |
42 Neutral | AU$13.57M | -2.24 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:LGP
Little Green Pharma Ltd.
0.08
-0.02
-23.00%
CNGGF
Cann Group
0.02
0.01
100.00%
HDRPF
Epsilon Healthcare Limited
―
―
―
AU:IDT
IDT Australia Limited
0.03
-0.06
-63.04%
AU:VIT
Cronos Australia Ltd.
0.03
-0.03
-51.67%
Little Green Pharma Ltd. Corporate Events
Little Green Pharma Discloses Final Director Interest as Angus Caithness Exits Board
Jun 9, 2026
Little Green Pharma has announced the cessation of director Angus Caithness from its board as of 1 June 2026 and provided a final notice of his interests in the company’s securities. The disclosure details his holdings of ordinary shares, re...
Little Green Pharma updates market on director Paul Long’s equity interests
Jun 9, 2026
Little Green Pharma has disclosed a change in the interests of director Paul Long, detailing his direct and indirect holdings in ordinary shares, options, and performance rights in the company. The notice confirms that there were no new performanc...
Little Green Pharma appoints new director and details sizeable escrowed shareholding
Jun 9, 2026
Little Green Pharma has appointed Brent Dennison as a director effective 1 June 2026, and lodged an initial director’s interest notice outlining his holdings in the company. Dennison holds 1,998,631 convertible and redeemable preference shar...
Little Green Pharma Completes Cannatrek Merger to Build Global Medicinal Cannabis Platform
Jun 1, 2026
Little Green Pharma has completed its scheme of arrangement to acquire 100% of Cannatrek, creating a combined group in which existing LGP shareholders own about 39.5% and Cannatrek shareholders hold roughly 60.5% of the fully diluted capital. The ...
Little Green Pharma Seeks ASX Quotation for Over 511 Million Shares
May 31, 2026
Little Green Pharma Ltd. has applied for quotation on the ASX of 511,068,631 ordinary fully paid shares under the code LGP, with an issue date of 1 June 2026. The application formalises the listing of these securities, which were issued as part of...
Little Green Pharma Issues Over 202 Million Unquoted Convertible Share Rights
May 31, 2026
Little Green Pharma Ltd has notified the market of the issue of 202,528,681 unquoted Convertible Share Rights, effective 1 June 2026. The new securities, created under a previously announced transaction, will not be quoted on the ASX and represent...
Little Green Pharma Seeks ASX Quotation for 450,000 New Shares
May 31, 2026
Little Green Pharma Ltd, an ASX-listed pharmaceutical company trading under the code LGP, has lodged an application with the exchange for quotation of additional ordinary fully paid shares. The filing reflects the company’s ongoing use of eq...
Little Green Pharma Seeks ASX Quotation for Additional Shares
May 31, 2026
Little Green Pharma Ltd has applied for quotation on the ASX of 165,605 new ordinary fully paid shares. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, marginally increasing the...
Little Green Pharma Director Trims Small Parcel of Shares
May 31, 2026
Little Green Pharma has disclosed a small on-market sale of shares by director Fleta Jennifer Solomon, as required under ASX listing rules. Solomon sold a total of 13,404 fully paid ordinary shares across two transactions on 26 and 28 May 2026 at ...
Little Green Pharma Seeks ASX Quotation for 1.2 Million Employee Plan Shares
May 31, 2026
Little Green Pharma Ltd, an ASX-listed medicinal cannabis company trading under ticker LGP, develops pharmaceutical-grade cannabis products and uses its equity to support employee participation in the business. The company operates in the regulate...
Little Green Pharma Cancels Lapsed Share and Performance Rights
May 31, 2026
Little Green Pharma has notified the market that 50,718 share rights and 4.5 million restricted performance rights have lapsed after the conditions attached to these securities were not met or became incapable of being satisfied. The cessation of ...
Little Green Pharma’s Cannatrek Acquisition Scheme Cleared by Court and Becomes Effective
May 25, 2026
Little Green Pharma Ltd, a leading medicinal cannabis producer and distributor with vertically integrated operations in Europe and Australia, supplies cannabis-based medicines across Australia and over a dozen export markets. The company operates ...
Little Green Pharma Seeks ASX Quotation for 1.24 Million New Shares
May 25, 2026
Little Green Pharma has applied for quotation on the ASX of 1,238,545 new ordinary fully paid shares, with an issue date of May 25, 2026. The securities arise from the exercise or conversion of existing options or other convertible instruments, mo...
Little Green Pharma Shareholders Approve Issue of Consideration Shares
May 22, 2026
Little Green Pharma Ltd. has released the results of its General Meeting of shareholders held on 22 May 2026. The company reported that the sole resolution put to shareholders, an approval to issue consideration shares, was passed on a poll with a...
Little Green Pharma outlines March quarter activities with extensive investor disclaimers
May 12, 2026
Little Green Pharma Ltd. released its March 2026 quarterly activities report and Appendix 4C investor presentation, outlining its recent operational and financial performance. The document is framed as general information for investors, emphasizin...
Little Green Pharma Updates on Cannatrek Deal, TGA Probe and Shareholder Vote
May 10, 2026
Little Green Pharma Ltd, an ASX-listed medicinal cannabis producer, is pursuing growth through the proposed acquisition of Cannatrek Ltd via a scheme of arrangement. The combined group would deepen its presence in Australia’s regulated medic...
Little Green Pharma Updates Court Date and Timetable for Cannatrek Acquisition
Apr 23, 2026
Little Green Pharma Ltd has updated the timetable for its proposed acquisition of Cannatrek Ltd, confirming that the Federal Court of Australia has adjourned the second court hearing to 25 May 2026. The company has set new key dates for shareholde...
Little Green Pharma Shareholders Approve Director Termination Benefits, Delay Key Scheme Vote
Apr 22, 2026
Little Green Pharma Ltd. reported the outcomes of its 22 April 2026 General Meeting, where shareholders voted on several resolutions relating to director termination benefits. Resolutions granting termination benefits to executive directors Angus ...
Little Green Pharma Delays Key Vote on Cannatrek Acquisition Scheme
Apr 21, 2026
Little Green Pharma has postponed shareholder consideration of a key resolution linked to its proposed all-share acquisition of Cannatrek Ltd., pushing the vote on issuing new ordinary and convertible shares from 22 April to 22 May 2026. The delay...
Cannatrek Shareholders Back Little Green Pharma Takeover Scheme
Apr 10, 2026
Little Green Pharma has reported that shareholders of Cannatrek Ltd have overwhelmingly approved the proposed scheme of arrangement for LGP to acquire 100% of Cannatrek’s issued capital. The resolution passed with 96.15% of Cannatrek shareho...
Little Green Pharma Advances Cannatrek Takeover With Supplementary Scheme Booklet Dispatch
Apr 1, 2026
Little Green Pharma has confirmed the dispatch of a supplementary scheme booklet to Cannatrek shareholders, providing additional information on LGP’s proposed acquisition of 100% of Cannatrek via a scheme of arrangement. The materials, avail...
Little Green Pharma issues supplementary booklet as Cannatrek scheme advances
Apr 1, 2026
Little Green Pharma has released a supplementary scheme booklet for its proposed acquisition of Cannatrek, after receiving Federal Court approval to dispatch the document. The booklet updates shareholders on the transaction timetable and provides ...
Little Green Pharma Sets Fully Virtual General Meeting for April 2026
Mar 22, 2026
Little Green Pharma Ltd has called a virtual general meeting of shareholders to be held on 22 April 2026, with participation exclusively via a Zoom webinar. The company will provide electronic access to the notice of meeting and related documents ...
Little Green Pharma Calls Virtual General Meeting for April 2026
Mar 22, 2026
Little Green Pharma Ltd. has called a General Meeting of shareholders to be held virtually via Zoom on Wednesday, 22 April 2026 at 3.30 p.m. AWST, with full access details to be provided through the ASX announcements platform and the company’...
Little Green Pharma Retains WA Production Facility as Sale-Leaseback Deal Collapses
Mar 18, 2026
Little Green Pharma has confirmed that a previously announced contract to sell and lease back its South-West Western Australian production facility has been terminated after the parties failed to reach commercial agreement on certain conditions pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.